Clozapine Versus Chlorpromazine for Treatment-Unresponsive Schizophrenia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00169039|
Recruitment Status : Terminated
First Posted : September 15, 2005
Last Update Posted : April 7, 2015
|Condition or disease||Intervention/treatment||Phase|
|Schizophrenia||Drug: Clozapine Drug: Chlorpromazine||Phase 4|
This is a longitudinal double-blind 12-week study of the clinical and biochemical response to clozapine or chlorpromazine in a group of treatment-refractory schizophrenic patients.
The study has 4 phases: (1) A recruitment period; (2) a period of discontinuation of psychotropic medication; (3) a drug-washout period; and (4) a 12-week double-blind trial of clozapine or chlorpromazine.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||66 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Clozapine Response and Biogenic Amines in Schizophrenia|
|Study Start Date :||December 1994|
|Study Completion Date :||February 2002|
- Clinical measures: Brief Psychiatric Rating Scale, Clinical Global Impression, Scale for the Assessment of Negative Symptoms, Simpson-Angus Scale, Abnormal Involuntary Movement Scale and Barnes Akathisia Scale.
- Biological measures: plasma and urinary samples of dopamine, norepinephrine and their metabolites.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00169039
|United States, Massachusetts|
|Commonwealth Research Center|
|Jamaica Plain, Massachusetts, United States, 02130|
|Principal Investigator:||Alan I Green, MD||Harvard Medical School|